Clinical Trial Search

Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants

Primary: Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment — 92; 69 percentage of participants

Primary: Estimate the Limits of Agreement Between Observed and Commanded Treadmill Belt Disturbance Parameters: Belt Displacement. — -8.5; 20.0; 2.1; -5.8 Mean Relative Error (%)

Primary: Mean Percent Change in LDL-C From Baseline To Week 12 — -10.6; 8.2 percent change — p=<0.0001

Primary: Recruitment of Participants. — 5; 5 Participants

Primary: Clinical Disease Activity Index (CDAI) Score at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With Methotrexate (MTX) — 18.1; 17; 16.6; 14.6 Units on a scale

Primary: Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 32; 36; 37; 43 Participants

Primary: Maximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia® — 7662.99; 7742.64; 8033.14 ng/ml

Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens

Primary: Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE) — 151; 90; 189; 91 Participants

Primary: Change in Body Mass Index (kg/m^2) — 0.14; 0.01 kg/m^2 (BMI change)

Primary: Bells Test — 14.2; 18.3; 19.3; 27.1 Number of items correct — p=0.1779

Primary: Pressure Ulcer of Grade >=1 on the National Pressure Ulcer Advisory Panel (NPUAP) Scale — 48; 94 Participants

Primary: Helpful/Empathetic Responses Toward Medial Mistrust in Hypothetical Patient Scenarios — 9.81; 9.26; 10.68; 8.90 score on a scale

Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 25.4; 10.7 percentage of participants — p=<0.0001